Forte Biosciences to be Acquired by argenx

Forte Biosciences, Inc. announced a definitive merger agreement with argenx BV, under which argenx will acquire Forte through a tender offer. This significant corporate action follows the company's report of positive topline data from a Phase 1b trial for vitiligo in July 2026. Financially, Forte Biosciences reported a net loss of $23.3 million for the second quarter of 2026, an increase from $11.2 million in the same period last year, driven by higher research and development expenses. The company's cash, cash equivalents, and short-term investments stood at $198.5 million as of June 30, 2026, bolstered by a public offering that raised $172.5 million gross in April 2026.